| Treatment selection in first-line metastatic renal cell carcinoma—the contemporary treatment paradigm in the age of combination therapy: a review V Navani, DYC Heng JAMA oncology 8 (2), 292-299, 2022 | 42 | 2022 |
| Outcomes for international metastatic renal cell carcinoma database consortium prognostic groups in contemporary first-line combination therapies for metastatic renal cell … MS Ernst, V Navani, JC Wells, F Donskov, N Basappa, C Labaki, SK Pal, ... European Urology 84 (1), 109-116, 2023 | 22 | 2023 |
| Influence of cohorting patients with Clostridium difficile infection on risk of symptomatic recurrence J Islam, E Cheek, V Navani, C Rajkumar, J Cohen, MJ Llewelyn Journal of Hospital Infection 85 (1), 17-21, 2013 | 22 | 2013 |
| Association of immune-related adverse events, hospitalization, and therapy resumption with survival among patients with metastatic melanoma receiving single-agent or … AS Watson, S Goutam, I Stukalin, BW Ewanchuk, M Sander, DE Meyers, ... JAMA Network Open 5 (12), e2245596-e2245596, 2022 | 18 | 2022 |
| How has acute oncology improved care for patients? V Navani Current Oncology 21 (3), 147-149, 2014 | 15 | 2014 |
| Imaging response to contemporary immuno-oncology combination therapies in patients with metastatic renal cell carcinoma V Navani, M Ernst, JC Wells, T Yuasa, K Takemura, F Donskov, ... JAMA network open 5 (6), e2216379-e2216379, 2022 | 14 | 2022 |
| Immune checkpoint blockade in solid organ tumours: choice, dose and predictors of response V Navani, MC Graves, NA Bowden, A Van Der Westhuizen British journal of clinical pharmacology 86 (9), 1736-1752, 2020 | 13 | 2020 |
| CABOSEQ: the effectiveness of cabozantinib in patients with treatment refractory advanced renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma … V Navani, JC Wells, DJ Boyne, WY Cheung, DM Brenner, BA McGregor, ... Clinical Genitourinary Cancer 21 (1), 106. e1-106. e8, 2023 | 12 | 2023 |
| Find the path of least resistance: Adaptive therapy to delay treatment failure and improve outcomes C Gedye, V Navani Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1877 (2), 188681, 2022 | 10 | 2022 |
| Real-world treatment patterns and effectiveness of targeted and immune checkpoint inhibitor-based systemic therapy in BRAF mutation-positive NSCLC AJW Gibson, A Pabani, ML Dean, G Martos, WY Cheung, V Navani JTO Clinical and Research Reports 4 (3), 100460, 2023 | 8 | 2023 |
| Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers V Navani, MC Graves, GC Marchett, H Mandaliya, NA Bowden, ... Pharmacology research & perspectives 9 (4), e00808, 2021 | 7 | 2021 |
| Business as unusual: medical oncology services adapt and deliver during COVID‐19 A Travers, K Adler, G Blanchard, T Bonaventura, J Charlton, F Day, ... Internal Medicine Journal 51 (5), 673-681, 2021 | 6 | 2021 |
| Impact of performance status on survival outcomes and health care utilization in patients with advanced NSCLC treated with immune checkpoint inhibitors DE Meyers, M Pasternak, S Dolter, HAI Grosjean, CA Lim, I Stukalin, ... JTO Clinical and Research Reports 4 (4), 100482, 2023 | 5 | 2023 |
| CABOSEQ: The efficacy of cabozantinib post up-front immuno-oncology combinations in patients with advanced renal cell carcinoma: Results from the International Metastatic Renal … V Navani, C Wells, DJ Boyne, WY Cheung, D Brenner, BA McGregor, ... Journal of Clinical Oncology 40 (6_suppl), 318-318, 2022 | 5 | 2022 |
| Immune-Related Adverse Events and Survival Among Patients With Metastatic NSCLC Treated With Immune Checkpoint Inhibitors S Cook, V Samuel, DE Meyers, I Stukalin, I Litt, R Sangha, DG Morris, ... JAMA Network Open 7 (1), e2352302-e2352302, 2024 | 4 | 2024 |
| Guillain-Barré syndrome as a paraneoplastic manifestation of disseminated squamous cell carcinoma V Navani, D Webster, SK Williams, D Agranoff Case Reports 2013, bcr2013009700, 2013 | 4 | 2013 |
| Characterization of patients with metastatic renal cell carcinoma experiencing complete response to first-line therapies: results from the International Metastatic Renal Cell … K Takemura, V Navani, MS Ernst, JC Wells, L Meza, SK Pal, JL Lee, H Li, ... The Journal of Urology 209 (4), 701-709, 2023 | 3 | 2023 |
| Impact of performance status on survival outcomes and health care utilization in patients with advanced non–small cell lung cancer treated with immune checkpoint inhibitors. DE Meyers, M Pasternak, S Dolter, HAI Grosjean, C Lim, I Stukalin, ... Journal of Clinical Oncology 40 (16_suppl), 9053-9053, 2022 | 3 | 2022 |
| Characterizing IMDC prognostic groups in contemporary first-line combination therapies for metastatic renal cell carcinoma (mRCC) MS Ernst, V Navani, JC Wells, F Donskov, NS Basappa, C Labaki, SK Pal, ... J. Clin. Oncol 40, 308, 2022 | 3 | 2022 |
| Progression-free survival gain: A reliable primary end point for drug registration that can accelerate patient access to urgently needed therapies DJ Stewart, T Ramsay, V Navani, G Liu, DM Jiang, G Batist Journal of clinical oncology: official journal of the American Society of …, 2024 | 2 | 2024 |
Daniel Y C HengTom Baker Cancer CenterVerified email at albertahealthservices.ca
